Skip to content

Study · Non-randomized trial · n = 27 · 2009

4 results

Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate.

Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jun 2009Cited by 32 (Europe PMC)

PMID19113926 (opens in a new tab)PMCIDPMC2683649 (opens in a new tab)DOI10.1359/jbmr.081250 (opens in a new tab)PepBankPUB-19113926
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In women on continued alendronate, procollagen propeptide increased during both teriparatide courses, with smaller increments during retreatment.

    In plain wordsIn women on alendronate, a bone formation marker increased during both teriparatide courses, with smaller increases during retreatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePropeptide of type I procollagen during initial treatment and retreatment
    Study

    n = 27

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 15 monthsAs given in this study (human).

    Measurements

    Median 3-month increment
    120%
    original course
    Median 3-month increment
    60%
    retreatment

    Source sentences

    Summary
    Bone formation indices (propeptide of type I procollagen and osteocalcin) increased during both teriparatide courses with median 3-mo increments of 120% and 72% above baseline during the original course and 60% and 40% above baseline during retreatment, respectively.
    1 context sentence
    Summary · context
    At that time, 32 patients, who remained at high risk of future fracture, were recruited into the retreatment protocol and 27 completed another course of teriparatide administered daily for 15 mo (including 15 from the original daily treatment group and 12 from the original cyclic treatment group).
  2. 02HumanNon-randomized trialActivity measurement

    In women on continued alendronate, osteocalcin increased during both teriparatide courses, with smaller increments during retreatment.

    In plain wordsIn women on alendronate, osteocalcin increased during both teriparatide courses, with smaller increases during retreatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOsteocalcin during initial treatment and retreatment
    Study

    n = 27

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 15 monthsAs given in this study (human).

    Measurements

    Median 3-month increment
    72%
    original course
    Median 3-month increment
    40%
    retreatment

    Source sentences

    Summary
    Bone formation indices (propeptide of type I procollagen and osteocalcin) increased during both teriparatide courses with median 3-mo increments of 120% and 72% above baseline during the original course and 60% and 40% above baseline during retreatment, respectively.
    1 context sentence
    Summary · context
    At that time, 32 patients, who remained at high risk of future fracture, were recruited into the retreatment protocol and 27 completed another course of teriparatide administered daily for 15 mo (including 15 from the original daily treatment group and 12 from the original cyclic treatment group).
  3. 03HumanNon-randomized trialEfficacy outcome

    In women on continued alendronate, spine BMD increased during the original daily teriparatide course and during retreatment.

    In plain wordsIn women on alendronate, spine bone density increased during the first daily teriparatide course and during retreatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpine BMD in original daily group
    Study

    n = 15

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 15 monthsAs given in this study (human).

    Measurements

    Spine BMD increment
    6.2%
    first daily course
    Spine BMD increment
    4.7%
    retreatment after daily course

    Source sentences

    Summary
    Mean spine BMD increments were 6.2% after the first daily course and 4.7% after retreatment and 4.1% after the first course of cyclic teriparatide and 4.9% after retreatment.
    1 context sentence
    Summary · context
    At that time, 32 patients, who remained at high risk of future fracture, were recruited into the retreatment protocol and 27 completed another course of teriparatide administered daily for 15 mo (including 15 from the original daily treatment group and 12 from the original cyclic treatment group).
  4. 04HumanNon-randomized trialEfficacy outcome

    In women on continued alendronate, spine BMD increased during the original cyclic teriparatide course and during daily retreatment.

    In plain wordsIn women on alendronate, spine bone density increased during the first cyclic teriparatide course and during daily retreatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpine BMD in original cyclic group
    Study

    n = 12

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 15 monthsAs given in this study (human).

    Measurements

    Spine BMD increment
    4.1%
    first cyclic course
    Spine BMD increment
    4.9%
    retreatment after cyclic course

    Source sentences

    Summary
    Mean spine BMD increments were 6.2% after the first daily course and 4.7% after retreatment and 4.1% after the first course of cyclic teriparatide and 4.9% after retreatment.
    1 context sentence
    Summary · context
    At that time, 32 patients, who remained at high risk of future fracture, were recruited into the retreatment protocol and 27 completed another course of teriparatide administered daily for 15 mo (including 15 from the original daily treatment group and 12 from the original cyclic treatment group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.